期刊文献+

免疫细胞调节骨转移瘤“恶性”循环的研究进展 被引量:1

原文传递
导出
摘要 排异是维持机体内外环境稳态是免疫系统的基本功能。免疫反应对抑制骨转移瘤生长、侵袭发挥重要作用。骨转移瘤骨骼微环境中,肿瘤细胞可以刺激破骨细胞生成、增强破骨细胞溶骨活性。骨质溶解释放出存储于骨内的生长因子,这些生长因子又进一步促进骨内肿瘤生长和分泌相关因子。肿瘤细胞和破骨细胞之间形成骨质破坏恶性循环。根据对骨转移瘤的调节效应免疫细胞分为3类:抗骨转移瘤的免疫细胞,促骨转移瘤的免疫细胞和双重调节性免疫细胞。免疫细胞参与调节骨转移瘤恶性循环。不同条件下免疫细胞功能可能发生改变,甚至完全相反。
机构地区 解放军第三
出处 《中华医学杂志》 CAS CSCD 北大核心 2016年第19期1546-1549,共4页 National Medical Journal of China
基金 北京市科委首都临床特色课题(z131107002213052 Z161100000516101)
  • 相关文献

参考文献30

  • 1Haduong JH, Blavier L, Baniwal SK, et al. Interaction between bone marrow stromal ceils and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis[J]. Int J Cancer,2015,137 (4) :797-809. DOI: 10. 1002/ijc. 29465.
  • 2雷明星,刘耀升,刘蜀彬.骨转移瘤系统性分子靶向治疗靶点与药理学制剂研究[J].中华骨科杂志,2016,36(1):58-64. 被引量:15
  • 3Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE ( BIG 01/04 ) randomised open-label phase 3 trial [J~. Lancet Oncol, 2014, 15(9) : 997-1006. DOI: 10. 1016/ S1470-2045 ( 14 ) 70302-X.
  • 4Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial[J]. Lancet Oncol, 2011, 12 (7) : 631-641. DOI : 10. 1016/S1470-2045 ( 11 ) 70122-X.
  • 5Pavlakis N, Schmidt R, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev ( Online ), 2005,20 ( 3 ) : CD003474. DOI : 10. 1002/14651858. CD003474.
  • 6Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-13 in homeostasis and cancer[ J]. Nat Rev Cancer, 2003, 3 ( 11 ) : 807-820. DOI: 10. 1038/nrc1208.
  • 7Shurin MR, Naiditch H, Zhong H, et al. Regulatory dendritic ceils: new targets for cancer immunotherapy [ J ]. Cancer Biol Ther, 2011, 11 (11) : 988-992. DOI: 10. 4161/cbt. 11. 11. 15543.
  • 8Kawalwc P, Paszulewicz A, Holko P, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. A systematic review and recta-analysis [ J ]. Archives of Medical Science, 2012, 8 (5) : 767-775. DOI: 10. 5114/aoms. 2012. 31610.
  • 9Zhang K, Kim S, Cremasco V, et al. CD8 + T ceils regulate bone tumor burden independent of osteoclast resorption [ J ]. Cancer Res, 2011, 71 (14) : 4799-4808. DOI: 10. 1158/0008-5472. CAN-10-3922.
  • 10Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 triM[J]. Lancet Oncol, 2014, 15(7) : 700-712. DOI: 10. 1016/S1470-2045 (14) 70189-5.

二级参考文献50

  • 1Todd D. Armstrong,Beth A. Pulaski,S. Ostrand-Rosenberg. Tumor antigen presentation: changing the rules[J] 1998,Cancer Immunology, Immunotherapy(2):70~74
  • 2E. Gilboa,Smita K. Nair,H. Kim Lyerly. Immunotherapy of cancer with dendritic-cell-based vaccines[J] 1998,Cancer Immunology, Immunotherapy(2):82~87
  • 3Burkhard Hennemann,Gabriele Beckmann,Annette Eichelmann,Annegret Rehm,R. Andreesen. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon γ and lipopolysaccharide[J] 1997,Cancer Immunology, Immunotherapy(5):250~256
  • 4Filiberto Belli,Flavio Arienti,J. Sulé-Suso,C. Clemente,Luigi Mascheroni,Alessandro Cattelan,Cristina Santantonio,Gian Francesco Gallino,Cecilia Melani,Stefania Rao,Mario P. Colombo,Michele Maio,Natale Cascinelli,G. Parmiani. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability[J] 1997,Cancer Immunology, Immunotherapy(4):197~203
  • 5Freeman AK, Sumathi VP, Jeys L. Metastatic tumours of bone[J].Surgery (United Kingdom), 2015, 33(1): 34-39. D01:10.1016/j.mpsur.2014.10.005.
  • 6Wang H, Shen W, Hu X,et al. Quetiapine inhibits osteoclastogen-esis and prevents human breast cancer-induced bone loss throughsuppression of the RANKL-mediated MAPK and NF-kB signalingpathways[J]. Breast Cancer Res Treat, 2015,149(3): 705-714.DOI: 10.1007/sl0549-015-3290-x.
  • 7Azim HA Jr, Peccatori FA, Broh6e S, et al. RANK - ligand(RANKL) expression in young breast cancer patients and duringpregnancy[J]. Breast Cancer Res, 2015,17: 24. DOI: 10.1186/sl3058-015-0538-7.
  • 8Ibrahim T, Sacanna E, Gaudio M, et al. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients[J]. Clin Breast Cancer, 2011, 11(6): 369- 375. DOI: 10.1016/j.clbc.2011.05.001.
  • 9Ibrahim T, Sacanna E, Gaudio M, et al. Role of RANK, RANKL,OPG, and CXCR4 tissue markers in predicting bone metastasesin breast cancer patients[J]. Clin Breast Cancer, 2011, 11(6): 369-375. DOI: 10.1016/j.clbc.2011.05.001.
  • 10Sanger N, Ruckhaberle E, Bianchini G, et al. OPG and PgR showsimilar cohort specific effects as prognostic factors in ER positivebreast cancer[J]. Mol Oncol, 2014,8(7): 1196 - 1207. DOI:10.1016/j.molonc.2014.04.003.

共引文献17

同被引文献12

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部